Publications by authors named "Francisco Javier Garcia-Latasa"
Article Synopsis
- Anti-tumor necrosis factor alpha (anti-TNF-α) drugs block the action of the cytokine TNF-α, which is linked to several diseases.
- These drugs are commonly used in treatments but have been associated with a rise in skin-related side effects.
- The observed increase in cutaneous adverse events raises concerns about the safety of these anti-TNF biologic treatments in patients.
The objective of the study was to evaluate efficacy and safety of ixekizumab in psoriasis patients under clinical practice conditions. Observational, retrospective, multicentre study that included patients with ixekizumab from March 2017 to March 2019. ≥ 90% reduction in the Psoriasis Area and Severity Index (PASI 90) and absolute PASI <2 were the parameters used to assess treatment response.
View Article and Find Full Text PDF